The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IPIG 2025 | The benefits of crovalimab for the treatment of PNH
Yasutaka Ueda, MD, PhD, Osaka University, Suita, Japan, highlights the unique features of the complement inhibitor crovalimab that may make it a superior treatment option for patients with paroxysmal nocturnal hemoglobinuria (PNH) when compared to other complement inhibitors. Dr Ueda notes that crovalimab’s subcutaneous route of administration, which can be completed at home and in under one minute, reduces the burden on patients and eliminates the need for frequent clinic visits. This interview took place at the 2nd International PNH Interest Group (IPIG) Conference in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, crovalimab is used every four weeks with subcutaneous injection. So it means that even when the patient complains about the sick pain, to have some pain for the injection then those patients could be dosed subcutaneously safely. It means that it doesn’t take so much time for subcutaneous injection. In less than one minute you could finish the dosing. So it reduces burden for the PNH patients...
So, crovalimab is used every four weeks with subcutaneous injection. So it means that even when the patient complains about the sick pain, to have some pain for the injection then those patients could be dosed subcutaneously safely. It means that it doesn’t take so much time for subcutaneous injection. In less than one minute you could finish the dosing. So it reduces burden for the PNH patients. Another thing is that you could give crovalimab for those patients at home care system. So if the patients are treated at home, they don’t have to come to clinic so often. One thing is that of course, crovalimab works for the PNH patients with C5 polymorphism who are resistant to eculizumab or ravulizumab.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
